NEWTON, Mass., March 29, 2017 /PRNewswire/ -- neoSurgical, LTD., a private medical technology company focused on advancing surgical wound healing, is pleased to report the execution of an exclusive distribution agreement with a global partner for the commercialization of neoClose® within Europe. The partner is a world leader in laparoscopic surgery with an extensive product portfolio available worldwide. This agreement anticipates initial product launch in Europe in May 2017.
Ronan Keating, neoSurgical's CTO, stated, "This agreement is an important milestone for our company and our pursuit of advancing surgical wound healing. The quality of our European partner, their longstanding dedication to patient wellbeing, and their ambitions for the products in the marketplace are a testament to the efficacy and benefit of neoClose®."
neoClose® brings a simple, intuitive and reliable solution to assist the surgeon in closing port site defects, up to 3cm, following laparoscopic abdominal surgery. By utilizing bio-absorbable anchors and a Vector-X closure, neoClose® is changing the standard of care in port site closure.
About neoSurgicalneoSurgical® is a commercial-stage company focused on being the global leader in advancing surgical wound healing. The company's initial product is neoClose®, approved for sale in the US and Europe and designed to be the new standard for Laparoscopic surgery port site closure, a potential $400 million opportunity. The company's neoClose® system for port site closure used in Laparoscopic surgery has now been used more than 20,000 times in hospitals across the United States.
To learn more, visit www.neosurgical.com
For media inquiries please contact [email protected]
Advertisement
Ronan Keating, neoSurgical's CTO, stated, "This agreement is an important milestone for our company and our pursuit of advancing surgical wound healing. The quality of our European partner, their longstanding dedication to patient wellbeing, and their ambitions for the products in the marketplace are a testament to the efficacy and benefit of neoClose®."
Advertisement
neoClose® brings a simple, intuitive and reliable solution to assist the surgeon in closing port site defects, up to 3cm, following laparoscopic abdominal surgery. By utilizing bio-absorbable anchors and a Vector-X closure, neoClose® is changing the standard of care in port site closure.
About neoSurgicalneoSurgical® is a commercial-stage company focused on being the global leader in advancing surgical wound healing. The company's initial product is neoClose®, approved for sale in the US and Europe and designed to be the new standard for Laparoscopic surgery port site closure, a potential $400 million opportunity. The company's neoClose® system for port site closure used in Laparoscopic surgery has now been used more than 20,000 times in hospitals across the United States.
To learn more, visit www.neosurgical.com
For media inquiries please contact [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neosurgical-signs-exclusive-distribution-agreement-with-global-medical-device-company-to-commercialize-neoclose-laparoscopic-port-closure-device-in-europe-300431145.html
SOURCE neoSurgical
